Volume : 13, Issue : 04, April – 2026
Title:
DEVELOPMENT AND CHARACTERIZATION OF CANAGLIFLOZIN LOADED POLYMERIC NANOPARTICLES USING BOX-BEHNKENDESIGN
Authors :
P. Prakash *, Lokanadhan Lahari
Abstract :
The purpose of this study was to development and characterization of Canagliflozin loaded polymeric nanoparticles using box-behnken design. Canagliflozin loaded polymeric nanoparticles, was prepared by solvent diffusion (Nano precipitation) method. Box-behnken design was introduced to optimize the formulation of polymeric nanoparticles Results: Fourier Transform Infra-Red (FTIR) studies indicate that the excipients added were compatible with the drug. The value of zeta potential Zeta potential value -28.99 is essential for effective stability and to inhibit aggregation of particles. The optimum formulation OPT-CN-PNP with entrapment efficiency 92.16±2.17% and particle size 132.23±7.26nm. Scanning electron microscopy and transmission electron microscopy images of the optimal OPT-CN-PNPs depicted that the particles appeared to be of spherical uniform shape. The size of most of the particles was found to be less than 200 nm.
Key words: polymeric nanoparticles, solvent diffusion, Box-behnken design, Scanning electron microscopy & Transmission electron microscopy.
Cite This Article:
Please cite this article in press P. Prakash et al., Development And Characterization Of Canagliflozin Loaded Polymeric Nanoparticles Using Box-Behnkendesign., Indo Am. J. P. Sci, 2026; 13(04).
REFERENCES:
1. McConnell H.M., Owicki J.C., Parce J.W. The cytosensor microphysiometer: biological applications of silicon technology, 257(5078), 1906-1912, 1992.
2. Chen H., Zhong Q. Processes improving the dispersibility of spray-dried zein nanoparticles using sodium caseinate. Food Hydrocolloids, 35, 358–366, 2014.
3. Teixeira J. Small-angle scattering by fractal systems. Journal of Applied Crystallography, 21 (6), 781–785, 1998.
4. Miyasaa S., Soichi A. Analysis of sulfhydryl groups in zein. Agriculture Biological Chemicals, 49 (5), 1417–1422, 1985.
5. Kasim N.A., Whitehouse M., Ramachandran C., Bermejo M., Lennernäs H., Hussain A.S., Junginger E., Stavchansky S.A., Midha K.K., Shah V.P., Amidon G.L. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Molecular Pharmaceutics, 1 (1), 85–96, 2004.
6. Lucio D., Irache J.M., Font M., Martínez-Ohárriz M.C. Supramolecular structure of glibenclamide and β-cyclodextrins complexes. International Journal of Pharmaceutics, 530 (1–2), 377–386, 2017.
7. Elle I.C., Olsen L.C.B., Pultz D., Rødkaer S.V., Faergeman N.J. Something worth dying for: molecular tools for the dissection of lipid metabolism in Caenorhabditis elegans. FEBS Lett, 584 (11), 2183–2193, 2010.
8. Ahmadi A., Khalili M., Farsadrooh M., Ghiasi M., Nahri-Niknafs B. Antihyperglycemic and antihyperlipidemic effects of newly synthesized glibenclamide analogues on streptozotocin-diabetic rats. Drug Research, 63 (12), 614–619, 2013.
9. Oussoren C, Zuidema J, Crommelin DJ, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection.: II. Influence of liposomal size, lipid composition and lipid dose. Biochimica et Biophysica Acta- Biomembranes. 1997 Sep 4;1328(2):261-72.
10. Freitas C, Muller R H. Stability determination of solid lipid nanoparticles (SLNTM) in aqueous dispersion after addition of electrolyte. J. Microencapsul. 1999; 16: 59–71.
11. Freitas RH, Muller, Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J of Pharm and Biopharm.1999; 125–132.
12. Freitas C, Muller R H, Spray-drying of solid lipid nanoparticles (SLN).Eur. J. Pharm. Biopharm. 1998; 46: 145–151.
13. Friedrich I, Muller-Goymann C, Characterization of solidified reverse micellar solutions (SRMS) and production development of SRMS- based nano suspensions. Eur. J. Pharm. Biopharm. 2003; 56 (1): 111-119.
14. Zanchetta B., Chaud M., Santana M. Self-emulsifying drug delivery systems (SEDDS) in pharmaceutical development. Journal of Advance Chemical Engineering, 5, 1–7, 2015.
15. Wild S., Roglic G. Global prevalence of diabetes: estimates for 2000 and projections for 2030. Diabetes Care, 27 (5), 1047–53, 2004.
16. Agabegi D Elizabeth; Agabegi, Steven S. Step-Up to Medicine (Step-Up Series). Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN 2008; 0- 7817-7153-6.
17. Lambert P. What is Type 1 Diabetes? Medicine, 30, 1–5, 2002.
18. Rother K.I. Diabetes treatment bridging the divide. The New England Journal of Medicine, 356 (15), 1499–501, 2007.
19. Lawrence J.M., Contreras R. “Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999–2005”. Diabetes Care, 31 (5) 899–904,2008.
20. Rathod K.B., Patel M.B., Parmar P.K., Kharadi S.R., Patel P.V., Patel K.S. Glimpses of current advances of nanotechnology in therapeutics. International Journal of Pharmaceutical Sciences, 3(1), 8-12, 2011.